MiRNA Sequencing and Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing), By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others), By End-use (Pharmaceutical & Biotechnology Industry, Research and Academic Institutes, Others), By Workflow (Library Preparation, Sequencing, Data Analysis & Storage), By Region & Competition, 2021-2031F
The Global MiRNA Sequencing and Assay Market is projected to expand from USD 24.26 Billion in 2025 to USD 35.56 Billion by 2031, reflecting a CAGR of 6.58%. These genomic technologies encompass methods designed to detect and quantify small non-coding RNA molecules that play a crucial role in regulating gene expression. This market trajectory is primarily driven by the increasing prevalence of chronic conditions, particularly cancer, which creates a strong demand for advanced biomarker discovery tools essential for early diagnosis and patient stratification. Additionally, the broader implementation of precision medicine initiatives and increased funding for genomic research provide substantial momentum for the sector's growth.
Despite these favorable drivers, the industry faces significant hurdles regarding the standardization of analytical protocols, a factor that complicates data reproducibility across various platforms. This technical variability presents a major challenge to widespread clinical adoption and the acquisition of regulatory approval. The critical need for these diagnostic capabilities is highlighted by the American Cancer Society, which estimated that approximately 2,001,140 new cancer cases would occur in the United States in 2024. Consequently, resolving consistency issues is vital to meeting the urgent demand for diagnostics capable of addressing the rising cancer burden.
Market Driver
The growth of the Global MiRNA Sequencing and Assay Market is largely propelled by the rising global incidence of cancer and chronic diseases, which intensifies the need for non-invasive biomarkers facilitating early detection and patient monitoring. MiRNAs are increasingly utilized in diagnostic workflows due to their stability in biological fluids, helping to improve clinical outcomes. This escalating demand is underscored by the World Health Organization's International Agency for Research on Cancer; in a February 2024 press release titled 'Global cancer burden growing,' the agency predicted over 35 million new cancer cases in 2050, a 77% increase from 2022 levels. Such projections highlight the necessity for scalable sequencing solutions capable of managing high-volume diagnostic screening for complex pathologies.
Simultaneously, a surge in public and private funding for genomic research is accelerating the advancement of liquid biopsy-based diagnostics. This capital influx allows biotechnology firms to refine assay sensitivity and validate clinical utility, effectively reducing barriers to market entry. For instance, in a February 2024 announcement titled 'Freenome Raises $254 Million to Advance Early Cancer Detection,' Freenome reported securing $254 million to extend its screening platform's reach. Furthermore, technological scalability is a key component of this ecosystem, as evidenced by Illumina's 2024 report of shipping 352 NovaSeq X instruments during the prior fiscal year, indicating a robust industrial capacity to support the increasing throughput demands of modern genomic assays.
Market Challenge
A significant barrier to the progression of the global miRNA sequencing and assay market is the lack of standardized analytical protocols. Because laboratories employ varying workflows, extraction methods, and sequencing platforms, the resulting data frequently lacks consistency. This technical variability makes it difficult to reproduce results, which is a fundamental requirement for clinical acceptance, and prevents stakeholders from effectively comparing findings across different studies. Consequently, healthcare providers often hesitate to adopt these assays for routine patient care, stalling widespread integration.
This fragmentation also directly impacts regulatory outcomes and commercial viability, as regulatory bodies require robust evidence of analytical validity. Inconsistent data significantly delays the approval process for new diagnostic tools, restricting the availability of reliable tests needed to support modern therapeutic approaches. The urgency of this issue is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines accounted for 35 percent of all new drug approvals in 2023. The inability to standardize testing for such therapies limits revenue potential and hampers the overall expansion of the miRNA sequencing landscape.
Market Trends
The integration of artificial intelligence into miRNA biomarker discovery is fundamentally reshaping the market by facilitating the rapid identification of complex disease signatures that traditional analytical methods often miss. Advanced algorithms can now process extensive multi-omics datasets to predict miRNA targets with high precision, accelerating the development of diagnostic panels. This technological shift is actively supported by major computing firms providing the necessary infrastructure; for instance, in a March 2024 press release titled 'NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health,' NVIDIA introduced over two dozen new microservices to deploy generative AI models across healthcare enterprises. These tools enable researchers to efficiently analyze genomic data and significantly reduce the time required to validate potential miRNA candidates for clinical applications.
Concurrently, the increasing adoption of single-cell miRNA sequencing is driving market expansion by resolving the cellular heterogeneity that bulk sequencing often obscures. This granular approach is particularly vital in oncology, where understanding the specific miRNA profiles of distinct cell populations within a tumor microenvironment is essential for developing targeted therapies. Manufacturers are facilitating this shift by releasing cost-effective platforms that lower financial barriers; highlighting this trend, 10x Genomics confirmed in its October 2024 'Third Quarter 2024 Financial Results' announcement the shipping of its GEM-X Flex and Universal Multiplex assays, which enable researchers to run millions of cells for less than one cent per cell. Such innovations are critical for transitioning single-cell profiling from niche academic research to broader clinical utility.
Key Market Players
In this report, the Global MiRNA Sequencing and Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global MiRNA Sequencing and Assay Market.
Available Customizations:
Global MiRNA Sequencing and Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Despite these favorable drivers, the industry faces significant hurdles regarding the standardization of analytical protocols, a factor that complicates data reproducibility across various platforms. This technical variability presents a major challenge to widespread clinical adoption and the acquisition of regulatory approval. The critical need for these diagnostic capabilities is highlighted by the American Cancer Society, which estimated that approximately 2,001,140 new cancer cases would occur in the United States in 2024. Consequently, resolving consistency issues is vital to meeting the urgent demand for diagnostics capable of addressing the rising cancer burden.
Market Driver
The growth of the Global MiRNA Sequencing and Assay Market is largely propelled by the rising global incidence of cancer and chronic diseases, which intensifies the need for non-invasive biomarkers facilitating early detection and patient monitoring. MiRNAs are increasingly utilized in diagnostic workflows due to their stability in biological fluids, helping to improve clinical outcomes. This escalating demand is underscored by the World Health Organization's International Agency for Research on Cancer; in a February 2024 press release titled 'Global cancer burden growing,' the agency predicted over 35 million new cancer cases in 2050, a 77% increase from 2022 levels. Such projections highlight the necessity for scalable sequencing solutions capable of managing high-volume diagnostic screening for complex pathologies.
Simultaneously, a surge in public and private funding for genomic research is accelerating the advancement of liquid biopsy-based diagnostics. This capital influx allows biotechnology firms to refine assay sensitivity and validate clinical utility, effectively reducing barriers to market entry. For instance, in a February 2024 announcement titled 'Freenome Raises $254 Million to Advance Early Cancer Detection,' Freenome reported securing $254 million to extend its screening platform's reach. Furthermore, technological scalability is a key component of this ecosystem, as evidenced by Illumina's 2024 report of shipping 352 NovaSeq X instruments during the prior fiscal year, indicating a robust industrial capacity to support the increasing throughput demands of modern genomic assays.
Market Challenge
A significant barrier to the progression of the global miRNA sequencing and assay market is the lack of standardized analytical protocols. Because laboratories employ varying workflows, extraction methods, and sequencing platforms, the resulting data frequently lacks consistency. This technical variability makes it difficult to reproduce results, which is a fundamental requirement for clinical acceptance, and prevents stakeholders from effectively comparing findings across different studies. Consequently, healthcare providers often hesitate to adopt these assays for routine patient care, stalling widespread integration.
This fragmentation also directly impacts regulatory outcomes and commercial viability, as regulatory bodies require robust evidence of analytical validity. Inconsistent data significantly delays the approval process for new diagnostic tools, restricting the availability of reliable tests needed to support modern therapeutic approaches. The urgency of this issue is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines accounted for 35 percent of all new drug approvals in 2023. The inability to standardize testing for such therapies limits revenue potential and hampers the overall expansion of the miRNA sequencing landscape.
Market Trends
The integration of artificial intelligence into miRNA biomarker discovery is fundamentally reshaping the market by facilitating the rapid identification of complex disease signatures that traditional analytical methods often miss. Advanced algorithms can now process extensive multi-omics datasets to predict miRNA targets with high precision, accelerating the development of diagnostic panels. This technological shift is actively supported by major computing firms providing the necessary infrastructure; for instance, in a March 2024 press release titled 'NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health,' NVIDIA introduced over two dozen new microservices to deploy generative AI models across healthcare enterprises. These tools enable researchers to efficiently analyze genomic data and significantly reduce the time required to validate potential miRNA candidates for clinical applications.
Concurrently, the increasing adoption of single-cell miRNA sequencing is driving market expansion by resolving the cellular heterogeneity that bulk sequencing often obscures. This granular approach is particularly vital in oncology, where understanding the specific miRNA profiles of distinct cell populations within a tumor microenvironment is essential for developing targeted therapies. Manufacturers are facilitating this shift by releasing cost-effective platforms that lower financial barriers; highlighting this trend, 10x Genomics confirmed in its October 2024 'Third Quarter 2024 Financial Results' announcement the shipping of its GEM-X Flex and Universal Multiplex assays, which enable researchers to run millions of cells for less than one cent per cell. Such innovations are critical for transitioning single-cell profiling from niche academic research to broader clinical utility.
Key Market Players
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- QIAGEN N.V.
- PerkinElmer, Inc.
- Abcam plc
- New England Biolabs, Inc.
- Takara Bio USA Inc.
- Lexogen GmbH
- Norgen Biotek Corp.
- Maravai LifeSciences Holdings, Inc
In this report, the Global MiRNA Sequencing and Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- MiRNA Sequencing and Assay Market, By Technology
- Sequencing by Synthesis
- Sequencing by Oligonucleotide Ligation and Detection (SOLiD)
- Nanopore Sequencing
- Sanger Sequencing
- Single Molecule Real-time (SMRT) Sequencing
- MiRNA Sequencing and Assay Market, By Application
- Cancer
- Polyglutamine Diseases
- Autoimmune Disease
- Schizophrenia
- Others
- MiRNA Sequencing and Assay Market, By End-use
- Pharmaceutical & Biotechnology Industry
- Research and Academic Institutes
- Others
- MiRNA Sequencing and Assay Market, By Workflow
- Library Preparation
- Sequencing
- Data Analysis & Storage
- MiRNA Sequencing and Assay Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global MiRNA Sequencing and Assay Market.
Available Customizations:
Global MiRNA Sequencing and Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing)
5.2.2. By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others)
5.2.3. By End-use (Pharmaceutical & Biotechnology Industry, Research and Academic Institutes, Others)
5.2.4. By Workflow (Library Preparation, Sequencing, Data Analysis & Storage)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Application
6.2.3. By End-use
6.2.4. By Workflow
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States MiRNA Sequencing and Assay Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Application
6.3.1.2.3. By End-use
6.3.1.2.4. By Workflow
6.3.2. Canada MiRNA Sequencing and Assay Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Application
6.3.2.2.3. By End-use
6.3.2.2.4. By Workflow
6.3.3. Mexico MiRNA Sequencing and Assay Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Application
6.3.3.2.3. By End-use
6.3.3.2.4. By Workflow
7. EUROPE MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Application
7.2.3. By End-use
7.2.4. By Workflow
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany MiRNA Sequencing and Assay Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Application
7.3.1.2.3. By End-use
7.3.1.2.4. By Workflow
7.3.2. France MiRNA Sequencing and Assay Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Application
7.3.2.2.3. By End-use
7.3.2.2.4. By Workflow
7.3.3. United Kingdom MiRNA Sequencing and Assay Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Application
7.3.3.2.3. By End-use
7.3.3.2.4. By Workflow
7.3.4. Italy MiRNA Sequencing and Assay Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Application
7.3.4.2.3. By End-use
7.3.4.2.4. By Workflow
7.3.5. Spain MiRNA Sequencing and Assay Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Application
7.3.5.2.3. By End-use
7.3.5.2.4. By Workflow
8. ASIA PACIFIC MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Application
8.2.3. By End-use
8.2.4. By Workflow
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China MiRNA Sequencing and Assay Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Application
8.3.1.2.3. By End-use
8.3.1.2.4. By Workflow
8.3.2. India MiRNA Sequencing and Assay Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Application
8.3.2.2.3. By End-use
8.3.2.2.4. By Workflow
8.3.3. Japan MiRNA Sequencing and Assay Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Application
8.3.3.2.3. By End-use
8.3.3.2.4. By Workflow
8.3.4. South Korea MiRNA Sequencing and Assay Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Application
8.3.4.2.3. By End-use
8.3.4.2.4. By Workflow
8.3.5. Australia MiRNA Sequencing and Assay Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Application
8.3.5.2.3. By End-use
8.3.5.2.4. By Workflow
9. MIDDLE EAST & AFRICA MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Application
9.2.3. By End-use
9.2.4. By Workflow
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia MiRNA Sequencing and Assay Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Application
9.3.1.2.3. By End-use
9.3.1.2.4. By Workflow
9.3.2. UAE MiRNA Sequencing and Assay Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Application
9.3.2.2.3. By End-use
9.3.2.2.4. By Workflow
9.3.3. South Africa MiRNA Sequencing and Assay Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Application
9.3.3.2.3. By End-use
9.3.3.2.4. By Workflow
10. SOUTH AMERICA MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Application
10.2.3. By End-use
10.2.4. By Workflow
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil MiRNA Sequencing and Assay Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Application
10.3.1.2.3. By End-use
10.3.1.2.4. By Workflow
10.3.2. Colombia MiRNA Sequencing and Assay Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Application
10.3.2.2.3. By End-use
10.3.2.2.4. By Workflow
10.3.3. Argentina MiRNA Sequencing and Assay Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Application
10.3.3.2.3. By End-use
10.3.3.2.4. By Workflow
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL MIRNA SEQUENCING AND ASSAY MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Thermo Fisher Scientific, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Illumina, Inc.
15.3. QIAGEN N.V.
15.4. PerkinElmer, Inc.
15.5. Abcam plc
15.6. New England Biolabs, Inc.
15.7. Takara Bio USA Inc.
15.8. Lexogen GmbH
15.9. Norgen Biotek Corp.
15.10. Maravai LifeSciences Holdings, Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing)
5.2.2. By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others)
5.2.3. By End-use (Pharmaceutical & Biotechnology Industry, Research and Academic Institutes, Others)
5.2.4. By Workflow (Library Preparation, Sequencing, Data Analysis & Storage)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Application
6.2.3. By End-use
6.2.4. By Workflow
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States MiRNA Sequencing and Assay Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Application
6.3.1.2.3. By End-use
6.3.1.2.4. By Workflow
6.3.2. Canada MiRNA Sequencing and Assay Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Application
6.3.2.2.3. By End-use
6.3.2.2.4. By Workflow
6.3.3. Mexico MiRNA Sequencing and Assay Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Application
6.3.3.2.3. By End-use
6.3.3.2.4. By Workflow
7. EUROPE MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Application
7.2.3. By End-use
7.2.4. By Workflow
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany MiRNA Sequencing and Assay Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Application
7.3.1.2.3. By End-use
7.3.1.2.4. By Workflow
7.3.2. France MiRNA Sequencing and Assay Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Application
7.3.2.2.3. By End-use
7.3.2.2.4. By Workflow
7.3.3. United Kingdom MiRNA Sequencing and Assay Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Application
7.3.3.2.3. By End-use
7.3.3.2.4. By Workflow
7.3.4. Italy MiRNA Sequencing and Assay Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Application
7.3.4.2.3. By End-use
7.3.4.2.4. By Workflow
7.3.5. Spain MiRNA Sequencing and Assay Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Application
7.3.5.2.3. By End-use
7.3.5.2.4. By Workflow
8. ASIA PACIFIC MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Application
8.2.3. By End-use
8.2.4. By Workflow
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China MiRNA Sequencing and Assay Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Application
8.3.1.2.3. By End-use
8.3.1.2.4. By Workflow
8.3.2. India MiRNA Sequencing and Assay Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Application
8.3.2.2.3. By End-use
8.3.2.2.4. By Workflow
8.3.3. Japan MiRNA Sequencing and Assay Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Application
8.3.3.2.3. By End-use
8.3.3.2.4. By Workflow
8.3.4. South Korea MiRNA Sequencing and Assay Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Application
8.3.4.2.3. By End-use
8.3.4.2.4. By Workflow
8.3.5. Australia MiRNA Sequencing and Assay Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Application
8.3.5.2.3. By End-use
8.3.5.2.4. By Workflow
9. MIDDLE EAST & AFRICA MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Application
9.2.3. By End-use
9.2.4. By Workflow
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia MiRNA Sequencing and Assay Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Application
9.3.1.2.3. By End-use
9.3.1.2.4. By Workflow
9.3.2. UAE MiRNA Sequencing and Assay Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Application
9.3.2.2.3. By End-use
9.3.2.2.4. By Workflow
9.3.3. South Africa MiRNA Sequencing and Assay Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Application
9.3.3.2.3. By End-use
9.3.3.2.4. By Workflow
10. SOUTH AMERICA MIRNA SEQUENCING AND ASSAY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Application
10.2.3. By End-use
10.2.4. By Workflow
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil MiRNA Sequencing and Assay Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Application
10.3.1.2.3. By End-use
10.3.1.2.4. By Workflow
10.3.2. Colombia MiRNA Sequencing and Assay Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Application
10.3.2.2.3. By End-use
10.3.2.2.4. By Workflow
10.3.3. Argentina MiRNA Sequencing and Assay Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Application
10.3.3.2.3. By End-use
10.3.3.2.4. By Workflow
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL MIRNA SEQUENCING AND ASSAY MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Thermo Fisher Scientific, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Illumina, Inc.
15.3. QIAGEN N.V.
15.4. PerkinElmer, Inc.
15.5. Abcam plc
15.6. New England Biolabs, Inc.
15.7. Takara Bio USA Inc.
15.8. Lexogen GmbH
15.9. Norgen Biotek Corp.
15.10. Maravai LifeSciences Holdings, Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
